Paul K Drain1, Elena Losina, Sharon M Coleman, Janet Giddy, Douglas Ross, Jeffrey N Katz, Ingrid V Bassett. 1. *Department of Medicine, Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA; †Department of Medicine, Divisions of Infectious Diseases, Massachusetts General Hospital, Boston, MA; ‡Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; §General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA; ‖Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ¶Boston University School of Public Health, Boston, MA; #Department of Medicine, McCord Hospital, Durban, South Africa; and **Department of Medicine, St. Mary's Hospital, Durban, South Africa.
Abstract
BACKGROUND: We assessed the role of urine lipoarabinomannan (LAM) grade and a second LAM test for HIV-associated pulmonary tuberculosis (TB) screening in outpatient clinics in South Africa. METHODS: We enrolled newly diagnosed HIV-infected adults (≥18 years) at 4 clinics, excluding those on TB therapy. Participants provided sputum for acid-fast bacilli (AFB) microscopy and culture. Nurses conducted 2 rapid urine LAM tests at the point-of-care and graded positive results from low (faint) to high (5+). Culture-confirmed pulmonary TB was the gold standard. We used area under receiver operating curves (AUROC) to compare screening strategies. RESULTS: Among 320 HIV-infected adults, median CD4 was 248 cells per cubic millimeter (interquartile range, 107-379/mm); 54 (17%) were TB culture positive. Fifty-two (16%) of all participants were LAM positive by either test; correlation between LAM tests was high. Among 10 "faint" positive results, 2 (20%) had culture-positive TB. Using ≥1+ LAM grade as positive, 1 LAM test had sensitivity of 41% [95% confidence interval (CI): 28% to 55%] and specificity of 92% (95% CI: 88% to 95%). A 2 LAM test strategy had a sensitivity of 43% (95% CI: 29% to 57%). One LAM test ≥1+ grade (AUROC = 0.66; 95% CI: 0.60 to 0.73) was significantly better than sputum AFB alone. The optimal strategy was sequentially performing 1 LAM test followed by sputum AFB if LAM grade <1+ (AUROC = 0.70; 95% CI: 0.63 to 0.77), which had sensitivity of 48% (95% CI: 34% to 62%) and specificity of 91% (95% CI: 87% to 94%). CONCLUSIONS: In this clinic-based study, "faint" line was a false-positive second urine LAM test added no value, and an optimal screening strategy was 1 LAM test followed by sputum AFB microscopy for urine LAM-negative people.
BACKGROUND: We assessed the role of urine lipoarabinomannan (LAM) grade and a second LAM test for HIV-associated pulmonary tuberculosis (TB) screening in outpatient clinics in South Africa. METHODS: We enrolled newly diagnosed HIV-infected adults (≥18 years) at 4 clinics, excluding those on TB therapy. Participants provided sputum for acid-fast bacilli (AFB) microscopy and culture. Nurses conducted 2 rapid urine LAM tests at the point-of-care and graded positive results from low (faint) to high (5+). Culture-confirmed pulmonary TB was the gold standard. We used area under receiver operating curves (AUROC) to compare screening strategies. RESULTS: Among 320 HIV-infected adults, median CD4 was 248 cells per cubic millimeter (interquartile range, 107-379/mm); 54 (17%) were TB culture positive. Fifty-two (16%) of all participants were LAM positive by either test; correlation between LAM tests was high. Among 10 "faint" positive results, 2 (20%) had culture-positive TB. Using ≥1+ LAM grade as positive, 1 LAM test had sensitivity of 41% [95% confidence interval (CI): 28% to 55%] and specificity of 92% (95% CI: 88% to 95%). A 2 LAM test strategy had a sensitivity of 43% (95% CI: 29% to 57%). One LAM test ≥1+ grade (AUROC = 0.66; 95% CI: 0.60 to 0.73) was significantly better than sputum AFB alone. The optimal strategy was sequentially performing 1 LAM test followed by sputum AFB if LAM grade <1+ (AUROC = 0.70; 95% CI: 0.63 to 0.77), which had sensitivity of 48% (95% CI: 34% to 62%) and specificity of 91% (95% CI: 87% to 94%). CONCLUSIONS: In this clinic-based study, "faint" line was a false-positive second urine LAM test added no value, and an optimal screening strategy was 1 LAM test followed by sputum AFB microscopy for urine LAM-negative people.
Authors: Emmett Keeler; Mark D Perkins; Peter Small; Christy Hanson; Steven Reed; Jane Cunningham; Julia E Aledort; Lee Hillborne; Maria E Rafael; Federico Girosi; Christopher Dye Journal: Nature Date: 2006-11-23 Impact factor: 49.962
Authors: Jonathan G Peter; Grant Theron; Richard van Zyl-Smit; Asheen Haripersad; Lynelle Mottay; Sarah Kraus; Anke Binder; Richard Meldau; Anneli Hardy; Keertan Dheda Journal: Eur Respir J Date: 2012-02-23 Impact factor: 16.671
Authors: Paul K Drain; Emily P Hyle; Farzad Noubary; Kenneth A Freedberg; Douglas Wilson; William R Bishai; William Rodriguez; Ingrid V Bassett Journal: Lancet Infect Dis Date: 2013-12-10 Impact factor: 25.071
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: Keertan Dheda; Virginia Davids; Laura Lenders; Teri Roberts; Richard Meldau; Daphne Ling; Laurence Brunet; Richard van Zyl Smit; Jonathan Peter; Clare Green; Motasim Badri; Leonardo Sechi; Surendra Sharma; Michael Hoelscher; Rodney Dawson; Andrew Whitelaw; Jonathan Blackburn; Madhukar Pai; Alimuddin Zumla Journal: PLoS One Date: 2010-03-24 Impact factor: 3.240
Authors: Stephen D Lawn; David J Edwards; Katharina Kranzer; Monica Vogt; Linda-Gail Bekker; Robin Wood Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: Helen Ayles; Albertus Schaap; Amos Nota; Charalambos Sismanidis; Ruth Tembwe; Petra De Haas; Monde Muyoyeta; Nulda Beyers Journal: PLoS One Date: 2009-05-19 Impact factor: 3.240
Authors: Stephanie Bjerrum; Ian Schiller; Nandini Dendukuri; Mikashmi Kohli; Ruvandhi R Nathavitharana; Alice A Zwerling; Claudia M Denkinger; Karen R Steingart; Maunank Shah Journal: Cochrane Database Syst Rev Date: 2019-10-21
Authors: R W Kubiak; J T Herbeck; S M Coleman; D Ross; K Freedberg; I V Bassett; P K Drain Journal: Int J Tuberc Lung Dis Date: 2018-11-01 Impact factor: 2.373
Authors: Jonny Peter; Grant Theron; Duncan Chanda; Petra Clowes; Andrea Rachow; Maia Lesosky; Michael Hoelscher; Peter Mwaba; Alex Pym; Keertan Dheda Journal: BMC Infect Dis Date: 2015-07-09 Impact factor: 3.090
Authors: Yasmeen Hanifa; Katherine L Fielding; Violet N Chihota; Lungiswa Adonis; Salome Charalambous; Alan Karstaedt; Kerrigan McCarthy; Mark P Nicol; Nontobeko T Ndlovu; Faieza Sahid; Gavin J Churchyard; Alison D Grant Journal: PLoS One Date: 2016-06-07 Impact factor: 3.240
Authors: Paul K Drain; Elena Losina; Sharon M Coleman; Janet Giddy; Douglas Ross; Jeffrey N Katz; Ingrid V Bassett Journal: BMC Pulm Med Date: 2016-11-14 Impact factor: 3.317